Back to search

University of British Columbia

The role of the angiotensin-II type I receptor in the control of breathing and central sleep apnea in normobaric hypoxia.

Abstract

dc:description

Nearly all healthy humans experience central sleep apnea (CSA) at high altitude (>4000 m). Sensitization of the carotid body (CB), the primary peripheral chemoreceptor (PCR), is thought to facilitate the enhanced ventilatory response to carbon dioxide (CO₂) and the development of CSA following hypoxic exposure. A local renin-angiotensin system within the CB and the angiotensin II type-I receptor (AT₁R) may play an important role in this pathway. We aimed to determine if losartan, an AT₁R antagonist, attenuates chemosensitization of the PCR and consequently the severity of hypoxia induced CSA. We hypothesized that losartan would attenuate CSA severity and PCR chemosensitivity. In a double blind, placebo-controlled, randomized cross-over study, male participants (n = 14) took either losartan or a placebo pill three times over 24 hours on experimental days. Sleep in a normobaric hypoxic chamber (FIO₂ = 0.135) was monitored using a type-I cardiopulmonary sleep system. Chemosensitivity was assessed using hypercapnic ventilatory response (HCVR) tests and a hypoxic apnea response (HAR) test and was completed prior to and following eight hours of sleep in hypoxia. HCVR tests were conducted in a hyperoxic (PETO₂ = 350 mmHg) and hypoxic (PETO₂ = 50 mmHg) background. The HAR consisted of 2 breaths of nitrogen (N₂) followed by a 20 second apnea and 40 seconds of recovery repeated 6 times. Compared to placebo, losartan did not reduce CSA severity (73 ± 15 and 75 ± 14, respectively; P = 0.8). Ventilatory reactivity was similar between losartan and placebo during the hyperoxic HCVR (3.6 ± 1.1 and 4.0 ± 0.6 l/min/mmHg, respectively; P = 0.4) and the hypoxic HCVR (5.3 ± 1.4 and 5.7 ± 0.7 l/min/mmHg, respectively; P = 0.9). Losartan did not affect the cardiorespiratory responses to hypoxic apneas. In summary, losartan did not reduce CSA severity, or the chemoreflex responsiveness before or after eight hours of acute nocturnal hypoxia. Therefore, the AT1R may not be involved in the chemosensitization of the PCR or the development of CSA in response to acute nocturnal hypoxia, in healthy young males.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Interdisciplinary Studies - Health and Exercise
Grantor dc:publisher
University of British Columbia
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Brown, Courtney

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/70521

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Brown, Courtney. The role of the angiotensin-II type I receptor in the control of breathing and central sleep apnea in normobaric hypoxia.. master's thesis, University of British Columbia, 2019. http://hdl.handle.net/2429/70521